Tokyo, Japan

Ikuko Nakamura



 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ikuko Nakamura: Innovator in Antifungal Compounds

Introduction

Ikuko Nakamura is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of antifungal agents, particularly through her innovative research and development of cyclic compounds. With a total of 2 patents, her work has the potential to impact the treatment of deep-seated mycoses.

Latest Patents

Nakamura's latest patents include a cyclic compound and salt thereof, which serves as a potent antifungal agent. This compound is particularly useful for treating deep-seated mycoses. The invention was developed after isolating cyclic compounds from culture liquids of a collected fungus. The research confirmed that these compounds possess strong antifungal activity, making them valuable as medicaments. Another notable patent involves a microorganism that produces compounds effective against mycotic sinusitis. This discovery was the result of extensive studies on naturally-occurring microorganisms, leading to the identification of a fungus that produces cyclic compounds with significant antifungal properties.

Career Highlights

Throughout her career, Ikuko Nakamura has worked with notable companies such as Astellas Pharma GmbH and Sirim Berhad. Her experience in these organizations has contributed to her expertise in the development of antifungal therapies.

Collaborations

Nakamura has collaborated with esteemed colleagues, including Koji Yoshikawa and Ryuichi Kanasaki. These partnerships have further enhanced her research and innovation in the field of antifungal agents.

Conclusion

Ikuko Nakamura's contributions to antifungal research through her patents and collaborations highlight her role as a leading inventor in this critical area of medicine. Her work continues to pave the way for advancements in the treatment of fungal infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…